Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

New research by Security Intelligence has revealed security risks in MLOps platforms including Azure ML, BigML and Google ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...